This study investigates the use of NKG2D CAR-NK cell therapy in individuals with pancreatic cancer. The purpose is to evaluate how this treatment works when used after second-line chemotherapy.
The focus of the study is to assess the safety and anti-tumor effects of the therapy. Researchers are looking at how well the treatment is tolerated and its effectiveness in managing the condition.
- Who can participate: Adults aged 18 to 75 with pancreatic cancer unresponsive to first-line therapy may qualify. Participants must have good organ function and a life expectancy of at least 3 months.
- Study details: Participants will receive investigational cell therapy following chemotherapy. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand